Mounjaro and Breastfeeding: Is Tirzepatide Safe for Nursing Mothers?

Mounjaro and breastfeeding is one of the most common questions new mothers ask when considering weight loss treatment after pregnancy. Tirzepatide, the active ingredient in Mounjaro, is a dual GIP/GLP-1 receptor agonist that has transformed how doctors approach obesity management. But for women who are nursing, the decision to start any medication requires careful consideration of both maternal and infant safety.

Postpartum weight retention affects a significant proportion of women in the UK, and the desire to return to a healthy weight is entirely understandable. However, the window during which a mother breastfeeds her baby is a uniquely sensitive period. What passes into breast milk, how much is absorbed, and whether it could affect a growing infant are all questions that deserve clear, evidence-based answers.

At CutKilo, we regularly speak with new mothers who want to begin Mounjaro treatment. This guide explains what the current clinical evidence says, what UK regulators recommend, and how to plan your weight loss journey safely around breastfeeding.

The short answer is that Mounjaro is not currently recommended for use during breastfeeding. Both the MHRA and NICE advise against prescribing tirzepatide to women who are nursing, primarily because long-term safety data in breastfeeding populations remains limited.

That said, the picture is not entirely bleak. A manufacturer-sponsored study of 11 lactating women given a single 5 mg dose of tirzepatide found that the drug was undetectable in 164 of 171 breast milk samples collected over 28 days. The cumulative amount detected in the remaining seven samples was equivalent to less than 0.02% of the maternal dose. These findings are reassuring, but they come from a small, single-dose study rather than the repeated dosing that real-world treatment requires.

Until larger studies confirm safety with ongoing use, UK prescribers are advised to err on the side of caution. At CutKilo, we follow this guidance and do not prescribe Mounjaro to women who are actively breastfeeding.

Understanding why tirzepatide is expected to transfer poorly into breast milk helps put the risk into perspective. Tirzepatide is a large peptide molecule with a molecular weight of approximately 4,814 Daltons. Molecules of this size do not cross biological membranes easily, which limits the amount that can pass from maternal blood into milk.

Even when small quantities do reach the milk, tirzepatide is a protein-based compound. An infant’s gastrointestinal tract is designed to break down proteins through enzymatic digestion. The National Institutes of Health LactMed database notes that tirzepatide is probably partially destroyed in the infant gut, meaning oral bioavailability to the baby is likely to be negligible.

This pharmacokinetic profile is consistent with other peptide-based therapies such as insulin, which has been used safely during breastfeeding for decades. However, tirzepatide’s longer half-life (approximately five days) and its novel dual-receptor mechanism mean that direct comparisons with insulin are imperfect, and regulators reasonably want more data before changing their stance.

In June 2025, the MHRA published updated guidance stating that GLP-1 receptor agonist medicines, including tirzepatide, should not be taken by people who are breastfeeding. The agency cited insufficient safety data to confirm that the medication would not cause harm to the nursing infant.

NICE echoes this position in its technology appraisal for tirzepatide, recommending that women who are breastfeeding should not be prescribed the drug until further evidence becomes available. The Summary of Product Characteristics (SmPC) for Mounjaro states that it is unknown whether tirzepatide is excreted in human milk and that a risk to newborns and infants cannot be excluded.

There was a notable development in April 2026, when the Patient Information Leaflet (PIL) for Mounjaro was updated to acknowledge that tirzepatide passes into breast milk in very low amounts and is not expected to be absorbed by a breastfed newborn or infant. While this updated wording reflects the lactation study data, it does not constitute a change in the prescribing recommendation. The formal advice from MHRA and NICE remains: do not prescribe during breastfeeding.

The postpartum period is physiologically demanding. Breastfeeding itself requires an additional 300 to 500 calories per day, and the hormonal shifts that support lactation influence metabolism, appetite, and fat storage. Introducing a potent appetite suppressant during this window could interfere with milk supply and maternal nutrition.

Tirzepatide works by slowing gastric emptying and reducing caloric intake. For a breastfeeding mother, significantly reduced food intake could compromise the quality and volume of breast milk. While the body can draw on fat stores to some extent, rapid weight loss during lactation has been associated with the release of fat-soluble environmental contaminants into breast milk, a consideration that is separate from the drug itself.

There is also the question of nausea and gastrointestinal side effects, which are common during the early stages of GLP-1 therapy. For a new mother managing sleep deprivation and infant care, adding significant nausea to the picture may be neither practical nor safe.

Although the direct pharmacological risk to the infant appears low based on available data, several indirect risks deserve consideration.

Reduced milk supply is the most commonly cited concern among lactation specialists. GLP-1 receptor agonists suppress appetite and slow gastric emptying, which can lead to significantly lower caloric intake. Sustained caloric restriction below approximately 1,500 calories per day has been linked to decreased milk production in some women, though individual responses vary.

Nutrient depletion is another consideration. Breastfeeding women have higher requirements for calcium, iron, zinc, and B vitamins. If Mounjaro causes a substantial reduction in food intake or triggers persistent nausea and vomiting, meeting these nutritional demands becomes more difficult.

Dehydration risk increases when GLP-1 therapy causes diarrhoea or vomiting, both of which are reported side effects of tirzepatide. Adequate hydration is essential for maintaining milk volume, and even mild dehydration can affect supply in some women.

Finally, there is the unknown factor. The existing lactation study involved a single dose, not the sustained weekly dosing used in clinical practice. Steady-state concentrations of tirzepatide in breast milk during ongoing treatment have not been measured, and the effects of cumulative low-level exposure on a developing infant remain unstudied.

The good news is that breastfeeding itself supports gradual weight loss. Women who exclusively breastfeed typically lose 0.5 to 1 kg per month in the first six months postpartum, as the caloric demands of milk production draw on maternal fat stores.

A structured, dietitian-guided eating plan that maintains at least 1,800 calories per day can support both milk production and steady fat loss. Prioritising lean protein, complex carbohydrates, and healthy fats ensures that nutritional quality is maintained for both mother and baby.

Gentle, progressive exercise can begin once a GP or midwife has confirmed that postnatal recovery is on track, typically from around six weeks postpartum for uncomplicated vaginal deliveries and eight to twelve weeks following caesarean section. Walking, postnatal yoga, and light resistance training are effective starting points that do not compromise lactation.

For women with a BMI of 30 or above who are struggling with postpartum weight, a conversation with a weight management specialist can help map out a realistic timeline. The goal is to create a plan that transitions seamlessly into pharmacological support once breastfeeding ends, so that no time is wasted.

Once breastfeeding has fully stopped, there is no mandatory waiting period before starting tirzepatide. The drug does not accumulate in breast tissue, and once lactation ceases, the considerations around milk transfer no longer apply.

In practice, many women find it helpful to allow a few weeks after weaning for hormonal levels to stabilise before beginning treatment. This also provides time to establish a consistent eating pattern, which makes it easier to manage the appetite-suppressing effects of Mounjaro and to distinguish between drug-related side effects and the normal hormonal fluctuations of the post-weaning period.

At CutKilo, we typically recommend a pre-treatment consultation two to four weeks after the last breastfeed. This appointment includes a full medical review, baseline blood tests, and a discussion of realistic weight loss goals. Women who have already read about how Mounjaro treatment works often find this conversation more productive, because they arrive with a clear understanding of what to expect.

Mounjaro is not recommended during breastfeeding under current MHRA and NICE guidance. While early lactation data suggests that very little tirzepatide reaches breast milk, the evidence base is too small to confirm safety with the repeated dosing used in clinical practice. The potential for reduced milk supply, nutritional compromise, and unknown cumulative effects means that the cautious approach is the right one.

The waiting period is temporary. Breastfeeding typically lasts six to twelve months, and the transition to Mounjaro treatment can begin promptly after weaning. In the meantime, structured nutrition and gentle exercise can support meaningful progress toward a healthier weight without compromising your baby’s feeding.

Can I take a single dose of Mounjaro while breastfeeding to see how I respond? This is not recommended. Even a single dose of tirzepatide remains active in the body for approximately five days due to its long half-life. While the lactation study used a single dose and found minimal transfer, the study was designed for research purposes under controlled conditions, not as a basis for clinical use during breastfeeding.

Does tirzepatide affect breast milk composition? There are no published studies examining whether tirzepatide alters the nutritional composition of breast milk beyond measuring the drug’s concentration. However, the significant reduction in maternal caloric intake that Mounjaro typically causes could indirectly affect milk quality if nutritional needs are not met.

Is Ozempic (semaglutide) safer than Mounjaro during breastfeeding? No. Semaglutide carries the same regulatory restrictions during breastfeeding as tirzepatide. The MHRA advises against all GLP-1 receptor agonists during lactation. There is no GLP-1 medication currently approved for use while nursing in the UK.

How soon after stopping breastfeeding can I start Mounjaro? There is no mandatory washout period. Once breastfeeding has fully ceased, you can begin treatment. At CutKilo, we suggest waiting two to four weeks after the last breastfeed to allow hormonal stabilisation before your initial consultation.

Will I lose the opportunity for effective weight loss if I wait until after breastfeeding? Not at all. Tirzepatide is equally effective regardless of when treatment begins. Clinical trials have shown consistent weight loss outcomes across a wide age range and varied starting points. Waiting until after breastfeeding does not reduce the drug’s efficacy.